Belimumab – an anti-BLyS human monoclonal antibody for rheumatoid arthritis

Bibliography

• Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. Am J Med 2007;120(11):936-9
   PubMed Web of Science ®Google Scholar
• Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 2006;5(7):564-76
   PubMed Web of Science ®Google Scholar
• Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2006;24:467-96
   PubMed Web of Science ®Google Scholar
• Looney RJ. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs 2010;70(5):529-40
   PubMed Web of Science ®Google Scholar
• Sabahi R, Anolik JH. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 2006;66(15):1933-48
   PubMed Web of Science ®Google Scholar
• Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003;48(6):1484-92
   PubMed Web of Science ®Google Scholar
• Moore PA, Belvedere O, Orr A, BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999;285(5425):260-3
   PubMed Web of Science ®Google Scholar
• Cancro MP. The BLyS family of ligands and receptors: an archetype for niche-specific homeostatic regulation. Immunol Rev 2004;202:237-49
   PubMed Web of Science ®Google Scholar
• Ding C, Jones G. Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline. Curr Opin Investig Drugs 2006;7(5):464-72
   PubMed Web of Science ®Google Scholar
• Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003;21:231-64
   PubMed Web of Science ®Google Scholar
• Khare SD, Sarosi I, Xia XZ, Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000;97(7):3370-5
   PubMed Web of Science ®Google Scholar
• Mackay F, Woodcock SA, Lawton P, Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190(11):1697-710
   PubMed Web of Science ®Google Scholar
• Moller B, Villiger PM. Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases. Springer Semin Immunopathol 2006;27(4):391-408
   PubMed Web of Science ®Google Scholar
• Ding C, Jones G. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases. Rev Recent Clin Trials 2006;1(3):193-200
   PubMedGoogle Scholar
• Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-alpha antagonists. Medicine 2005;84(5):291-302
   PubMed Web of Science ®Google Scholar
• Belimumab: anti-BLyS monoclonal antibody; Benlysta; BmAb; LymphoStat-B. Drugs R D 2010;10(1):55-65
   PubMedGoogle Scholar
• Baker KP, Edwards BM, Main SH, Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003;48(11):3253-65
   PubMed Web of Science ®Google Scholar
• Stohl W, Hilbert DM. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol 2012;30(1):69-77
   PubMed Web of Science ®Google Scholar
• Halpern WG, Lappin P, Zanardi T, Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci 2006;91(2):586-99
   PubMed Web of Science ®Google Scholar
• Cai W, Chen C, Zhong ZJ, Bioavailability, pharmacokinetics, and safety of belimumab administered subcutaneously in healthy subjects. Arthritis Rheum 2012;64(S10):616
   Google Scholar
• Stohl W, Chatham W, Weisman M, Belimumab (BmAb), a novel fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), selectively modulates B-cell sub-populations and immunoglobulins in a heterogeneous rheumatoid arthritis subject population. Arthritis Rheum 2005;52:S444
   Web of Science ®Google Scholar
• Furie R, Stohl W, Ginzler EM, Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10(5):11
   Google Scholar
• Furie R, Stohl W, Ginzler E, Safety, pharmacokinetic and pharmacodynamic results of a phase 1 single and double dose-escalation study of lymphostat-B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum 2003;48:S377
   Web of Science ®Google Scholar
• McKay J, Chwalinska-Sadowska H, Boling E. Belimumab (BmAb), a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population. Arthritis Rheum 2005;52(9):S710-11
   PubMed Web of Science ®Google Scholar
• Merrill JT, Wallace DJ, McKay J. Long-term safety profile of belimumab (fully human monoclonal antibody to BLyS) in patients with systematic lupus erythematosus (SLE). Ann Rheum Dis 2008;67(Suppl 2):217
   Google Scholar
• Merrill JT, Furie RA, Wallace DJ, Sustained disease improvement and safety profile over the 1500 patient-year experience (6 years) with belimumab in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63(S10):584
   Google Scholar
• Genovese M, Filipowicz-Sosnowska A, Merrill JT. Differential responsiveness to belimumab in combination with standard of care therapy in RF+, TNF alpha-inhibitor and methotrexate partial responder subgroups of subjects with moderate-severe rheumatoid arthritis. Arthritis Rheum 2005;52(9):S738
   Web of Science ®Google Scholar
• St Clair EW, Tedder TF. New prospects for autoimmune disease therapy: B cells on deathwatch. Arthritis Rheum 2006;54(1):1-9
   PubMed Web of Science ®Google Scholar
• Edwards JC, Szczepanski L, Szechinski J, Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350(25):2572-81
   PubMed Web of Science ®Google Scholar
• Lavie F, Miceli-Richard C, Ittah M, Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007;66(5):700-3
   PubMed Web of Science ®Google Scholar
• Vallerskog T, Heimburger M, Gunnarsson I, Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006;8(6):R167
   PubMedGoogle Scholar